Gestational diabetes & diabetes in pregnancy
The Cost of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Type 1 Diabetes Pregnancies in the United States: A Cost-Consequences Analysis Using Real-World Evidence
Authors' conclusion
This study adds to the growing evidence base that the increased costs of CGM use versus SMBG to manage T1D pregnancies are likely offset by better neonatal health outcomes.
Study context
- Population
- T1D pregnancies in the United States; real-world evidence from a retrospective chart review at the Barbara Davis Center for Diabetes
- Exposure
- Continuous glucose monitoring (CGM) vs self-monitoring of blood glucose (SMBG)
- Outcome
- Per-person cost, inclusive of NICU spending (base case: per-label CGM use, per-guideline finger-stick frequency)
Methodological detailsbased on real-world evidence from a retrospective chart review, base-case analysis, real-world scenario analysis, probabilistic sensitivity analysis
- Based on real-world evidence from a retrospective chart review
- Base-case analysis
- Real-world scenario analysis
- Probabilistic sensitivity analysis
Main finding
As reported in the abstract
CGM
$16,254
SMBG
$15,182
Observational data: associations, not effects.
Further findings
| Outcome | CGM | SMBG |
|---|---|---|
| Per-person cost, real-world scenario analysis | $13,708 | $14,524 |
Neonatal intensive care unit (NICU) admission costs (both analyses)
- Cost savings for NICU admissions with CGM use
- $2,903
Probabilistic sensitivity analysis
- CGM cost saving, base-case model iterations
- 25%
- CGM cost saving, real-world model iterations
- 46%
Original publication
The Cost of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Type 1 Diabetes Pregnancies in the United States: A Cost-Consequences Analysis Using Real-World Evidence. Diabetes Technol Ther. Published 19 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →